Related Content
Pulmonary Fibrosis
FIBRONEER™ trials for IPF, other progressive fibrosing ILDs
Donald Zoz, M.D., Director and Senior Clinical Program Leader for Pulmonary Fibrosis at Boehringer Ingelheim, discusses the unmet needs of patients with IPF and other forms of progressive fibrosing ILDs and the FIBRONEER™ global clinical program
Read more
Related Press Releases
September 16, 2024
Topline results from Boehringer's Phase III IPF Study
July 25, 2023